• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

Obesity Briefs from the AACE Annual Scientific & Clinical Congress

Slideshow

Highlights include: POC A1c testing in prediabetes screening, first-year weight loss after bariatric surgery, and predicting fracture risk in obese patients. 

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
Novel GLP-1/GLP-2 Agent Reduces Body Weight by Up to 8.3% in Phase 1b Obesity Trial

Novel GLP-1/GLP-2 Agent Reduces Body Weight by Up to 8.3% in Phase 1b Obesity Trial

Sydney Jennings
July 7th 2025
Article

ADA 2025: Dapiglutide showed promising safety and weight loss results in a phase 1b trial, targeting obesity and inflammation with once-weekly dosing.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Mifepristone Reduced HbA1c, Body Weight in Adults with Hypercortisolism and Inadequately Controlled T2D: CATALYST Trial Treatment Phase

Mifepristone Reduced HbA1c, Body Weight in Adults with Hypercortisolism and Inadequately Controlled T2D: CATALYST Trial Treatment Phase

Sydney Jennings
June 24th 2025
Article

ADA 2025: Mifepristone lowered HbA1c levels by about 1.5% over 24 weeks vs placebo among participants with hypercortisolism and inadequately controlled T2D.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Sydney Jennings
July 22nd 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

Once-Weekly Insulin Efsitora Comparable to Daily Glargine for Hyperglycemia in Adults with Type 2 Diabetes / image credit ADA Julio Rosenstock, MD

Once-Weekly Insulin Efsitora Comparable to Daily Glargine for Hyperglycemia in Adults with Type 2 Diabetes

Grace Halsey
June 23rd 2025
Article

ADA 2025: Insulin efsitora proved noninferior to daily insulin glargine for reducing HbA1c, resulted in fewer episodes of hypoglycemia, and required fewer dose adjustments.

ADA Standards of Care for Overweight and Obesity to Debut at 2025 Scientific Sessions / ©design36/shutterstock.com

ADA Standards of Care for Overweight and Obesity to Debut at 2025 Scientific Sessions

Grace Halsey
June 20th 2025
Article

The ADA unveils the association's first Standards of Care for Overweight and Obesity, with a chapter on weight stigma and bias one of the first released.

© 2025 MJH Life Sciences

All rights reserved.